AU2017295038B2 - 5-hydroxytryptamine 1B receptor-stimulating agent for skin and/or hair repair - Google Patents

5-hydroxytryptamine 1B receptor-stimulating agent for skin and/or hair repair Download PDF

Info

Publication number
AU2017295038B2
AU2017295038B2 AU2017295038A AU2017295038A AU2017295038B2 AU 2017295038 B2 AU2017295038 B2 AU 2017295038B2 AU 2017295038 A AU2017295038 A AU 2017295038A AU 2017295038 A AU2017295038 A AU 2017295038A AU 2017295038 B2 AU2017295038 B2 AU 2017295038B2
Authority
AU
Australia
Prior art keywords
skin
hair
vortioxetine
receptor
hydroxytryptamine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
AU2017295038A
Other languages
English (en)
Other versions
AU2017295038A1 (en
Inventor
Fabrice Bruno Chretien
Raphael GAILLARD
Pierre ROCHETEAU
Nicolas TORNO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite Paris Cite
Centre Hospitalier Sainte Anne
Institut Pasteur
Original Assignee
Universite Paris Cite
Centre Hospitalier Sainte Anne
Institut Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite Paris Cite, Centre Hospitalier Sainte Anne, Institut Pasteur filed Critical Universite Paris Cite
Publication of AU2017295038A1 publication Critical patent/AU2017295038A1/en
Application granted granted Critical
Publication of AU2017295038B2 publication Critical patent/AU2017295038B2/en
Assigned to INSTITUT PASTEUR, CENTRE HOSPITALIER SAINTE ANNE PARIS, UNIVERSITÉ PARIS CITÉ reassignment INSTITUT PASTEUR Request for Assignment Assignors: CENTRE HOSPITALIER SAINTE ANNE PARIS, INSTITUT PASTEUR, UNIVERSITE PARIS DESCARTES
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/41—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4933—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having sulfur as an exocyclic substituent, e.g. pyridinethione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/002—Preparations for repairing the hair, e.g. hair cure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/88—Two- or multipart kits
    • A61K2800/884—Sequential application
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/91—Injection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Birds (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
AU2017295038A 2016-07-15 2017-07-13 5-hydroxytryptamine 1B receptor-stimulating agent for skin and/or hair repair Expired - Fee Related AU2017295038B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IB2016001136 2016-07-15
IBPCT/IB2016/001136 2016-07-15
PCT/EP2017/067791 WO2018011382A1 (en) 2016-07-15 2017-07-13 5-hydroxytryptamine 1b receptor-stimulating agent for skin and/or hair repair

Publications (2)

Publication Number Publication Date
AU2017295038A1 AU2017295038A1 (en) 2019-01-24
AU2017295038B2 true AU2017295038B2 (en) 2022-09-22

Family

ID=56787641

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017295038A Expired - Fee Related AU2017295038B2 (en) 2016-07-15 2017-07-13 5-hydroxytryptamine 1B receptor-stimulating agent for skin and/or hair repair

Country Status (10)

Country Link
US (1) US20190290641A1 (https=)
EP (1) EP3484462B1 (https=)
JP (1) JP2019524723A (https=)
KR (1) KR20190038840A (https=)
CN (1) CN110022869A (https=)
AU (1) AU2017295038B2 (https=)
BR (1) BR112019000706A8 (https=)
CA (1) CA3030054A1 (https=)
MX (1) MX386989B (https=)
WO (1) WO2018011382A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX386470B (es) 2015-07-17 2025-03-18 Pasteur Institut Agente estimulador del receptor 5-hidroxi triptamina 1b para usarse como un promotor de la autorrenovación y/o diferenciación de células satélite.
US11013830B2 (en) 2015-11-20 2021-05-25 Institut Pasteur 5-hydroxytryptamine 1B receptor-stimulating agent for enhancing in vivo engraftment potential
CA3101420A1 (en) * 2018-06-20 2019-12-26 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
CN115919860B (zh) * 2022-12-05 2023-11-10 中国药科大学 氟班色林在制备治疗雄激素脱发药物中的用途

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003029232A1 (en) * 2001-10-04 2003-04-10 H. Lundbeck A/S Phenyl-piperazine derivatives as serotonin reuptake inhibitors
WO2007148341A2 (en) * 2006-06-22 2007-12-27 Ramot At Tel Aviv University Ltd. Novel serotonin reuptake inhibitors as drugs having peripheral-system-restricted activity
WO2008078353A1 (en) * 2006-12-22 2008-07-03 Medestea Internazionale S.P.A. A novel use of antidepressant compounds and related compositions
WO2011048496A1 (en) * 2009-10-23 2011-04-28 Fortuderm, Ltd. Triptans for the treatment of psoriasis
WO2014190063A1 (en) * 2013-05-21 2014-11-27 Wynberg Jason B Methods for the treatment of premature ejaculation

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63203625A (ja) 1987-02-19 1988-08-23 Kao Corp ５α−リダクタ−ゼ阻害剤
FR2739553B1 (fr) 1995-10-06 1998-01-02 Oreal Utilisation d'antagonistes de la bradykinine pour stimuler ou induire la pousse des cheveux et/ou stopper leur chute
FR2758263B1 (fr) * 1997-01-16 1999-12-17 Oreal Utilisation d'un antagoniste ou d'un agoniste de serotonine specifiques respectivement du recepteur 5ht2 et 5ht1d dans une composition cosmetique ou dermatologique pour peaux sensibles et composition obtenue
FR2778558B1 (fr) 1998-05-12 2001-02-16 Oreal Utilisation d'inhibiteur de metalloproteinases pour induire et/ou stimuler la croissance des cheveux ou des poils et/ou freiner leur chute
ES2147538B1 (es) 1999-01-29 2001-04-01 Revlon Consumer Prod Corp Una locion capilar con propiedades mejoradas en su accion protectora del cabello y preventiva de su caida, y de reduccion de los efectos externos de la alopecia androgenetica y con ello de la caida del cabello.
JP3441665B2 (ja) 1999-02-04 2003-09-02 株式会社資生堂 （２−置換オキシフェニル）アルカンアミド誘導体及び養毛剤、皮膚外用剤
US20060052405A1 (en) 2000-07-19 2006-03-09 Knowles W R Hair loss prevention
FR2812192B1 (fr) 2000-07-28 2003-01-31 Oreal Utilisation d'antagonistes de recepteur des prostaglandines ep-3 comme agent cosmetique permettant d'attenuer, de diminuer ou d'arreter la chute des cheveux et des poils
DE50012119D1 (de) * 2000-09-22 2006-04-13 Perlei Medical Producte Gmbh Verwendung von Antifibrinolytika für die Präparation und Herstellung von Tupfern, Kompressen oder Pflaster
DK1262177T3 (da) 2001-05-31 2006-11-20 Pfizer Prod Inc Medicinsk brug af thyromimetiske forbindelser til behandling af hårtab og kompositioner
EP1435899B1 (en) 2001-09-28 2009-03-11 LG Household &amp; Health Care Ltd. A composition for promoting hair growth
US6860042B2 (en) 2002-07-19 2005-03-01 Walker-Dawson Interests, Inc. Excavation system employing a jet pump
US20070292461A1 (en) * 2003-08-04 2007-12-20 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
DE60323533D1 (de) 2002-11-12 2008-10-23 Warner Lambert Co Methode zur stimulierung von haarwuchs auf der basis von benzopyranen
BRPI0406778A (pt) 2003-01-17 2006-01-17 Warner Lambert Co Antagonistas de receptores de androgênio
PT1636236E (pt) 2003-05-22 2013-12-16 Nerviano Medical Sciences Srl Derivados de pirazol-quinazolina, processo para sua preparação e sua utilização como inibidores de cinase
US20050118282A1 (en) 2003-09-16 2005-06-02 Aphios Corporation Compositions and methods for inhibiting 5-alpha reductase
AR041407A1 (es) 2003-09-26 2005-05-18 Nestor Alberto Kerner Oligonucleotidos antiandrogenos utilizables en el tratamiento de patologias dermatologicas relacionadas con el metabolismo de los androgenos, sus composiciones farmaceuticas y sus usos y metodos de tratamiento
US20060009430A1 (en) 2004-07-01 2006-01-12 Kelly Gregory J Composition for the prevention and treatment of the detrimental effects of dihydrotestosterone
EP1781598A1 (en) 2004-07-08 2007-05-09 Warner-Lambert Company LLC Androgen modulators
DE202006007482U1 (de) 2006-05-10 2006-07-20 Sentner, Thomas Leuchtmöbel
EP2044043B2 (en) * 2006-06-16 2021-03-03 H. Lundbeck A/S 1- ý[- (2, 4-dimethylphenylsulfanyl) -phenyl]piperazine hydrobromide as a compound with combined serotonin reuptake, 5-ht3 and 5-ht1a activity for the treatment of cognitive impairment
FR2903984B1 (fr) 2006-07-24 2008-10-03 Genfit Sa Derives d'imidazolones substitues, preparation et utilisations
WO2008084286A2 (en) * 2006-10-25 2008-07-17 Arterial Remodeling Technologies, S.A. Method for expansion and deployment of polymeric structures including stents
US7737149B2 (en) 2006-12-21 2010-06-15 Astrazeneca Ab N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof
ITTO20060918A1 (it) * 2006-12-22 2008-06-23 Chiara Cesano Composizione cosmetica e farmaceutica e mezzo di coltura per la rigenerazione del tessuto cutaneo, e relativi usi
PT2585470T (pt) 2010-06-23 2017-03-06 Hanmi Science Co Ltd Novos derivados fundidos de pirimidina para inibição da actividade da tirosina cinase
AU2013305563B2 (en) * 2012-08-24 2018-09-27 Integurx Therapeutics, Llc Chemical compositions and methods for enhancing transdermal delivery of therapeutic agents
US9399039B1 (en) * 2015-06-30 2016-07-26 University Of South Florida Inhibitors of the FKBP51 protein from a high-throughput drug screen and methods of use

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003029232A1 (en) * 2001-10-04 2003-04-10 H. Lundbeck A/S Phenyl-piperazine derivatives as serotonin reuptake inhibitors
WO2007148341A2 (en) * 2006-06-22 2007-12-27 Ramot At Tel Aviv University Ltd. Novel serotonin reuptake inhibitors as drugs having peripheral-system-restricted activity
WO2008078353A1 (en) * 2006-12-22 2008-07-03 Medestea Internazionale S.P.A. A novel use of antidepressant compounds and related compositions
WO2011048496A1 (en) * 2009-10-23 2011-04-28 Fortuderm, Ltd. Triptans for the treatment of psoriasis
WO2014190063A1 (en) * 2013-05-21 2014-11-27 Wynberg Jason B Methods for the treatment of premature ejaculation

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ALEX MALININ, BENJAMIN OSHRINE, VICTOR SEREBRUANY: "Treatment with selective serotonin reuptake inhibitors for enhancing wound healing", MEDICAL HYPOTHESES, EDEN PRESS, PENRITH., US, vol. 63, no. 1, 1 January 2004 (2004-01-01), US , pages 103 - 109, XP055348687, ISSN: 0306-9877, DOI: 10.1016/j.mehy.2003.10.021 *
NGUYEN: JOURNAL OF INVESTIGATIVE DERMATOLOGY, S133 PUBLISHED IN ISSUE: MAY 2016, 1 May 2016 (2016-05-01), XP055348757, Retrieved from the Internet [retrieved on 20170222] *

Also Published As

Publication number Publication date
WO2018011382A1 (en) 2018-01-18
CN110022869A (zh) 2019-07-16
KR20190038840A (ko) 2019-04-09
EP3484462A1 (en) 2019-05-22
EP3484462B1 (en) 2022-12-14
US20190290641A1 (en) 2019-09-26
BR112019000706A2 (pt) 2019-05-07
MX2019000600A (es) 2019-06-13
JP2019524723A (ja) 2019-09-05
CA3030054A1 (en) 2018-01-18
MX386989B (es) 2025-03-19
AU2017295038A1 (en) 2019-01-24
BR112019000706A8 (pt) 2022-12-06

Similar Documents

Publication Publication Date Title
AU2017295038B2 (en) 5-hydroxytryptamine 1B receptor-stimulating agent for skin and/or hair repair
JP2001510154A (ja) カッパアゴニスト化合物、製剤、ならびにそれらによる掻痒の予防法および治療法
JP7159302B2 (ja) 線維性疾患の治療のための方法
AU2010248292B2 (en) Composition for preventing hair loss or for stimulating hair growth
US20210330863A1 (en) 5-hydroxytryptamine 1b receptor-stimulating agent for enhancing in vivo engraftment potential
CN101903009B (zh) 含有脱硫生物素及其衍生物的局部组合物和治疗皮肤的方法
EP3573957A1 (en) Compositions and methods for blocking sodium channels
JPWO2003066100A1 (ja) 発毛促進剤、経皮適用製剤及び発毛促進方法
CA2339996C (en) Method for treating hot flashes in humans
JP2015516452A (ja) （１ｒ，４ｒ）−６’−フルオロ−Ｎ，Ｎ−ジメチル−４−フェニル−４’，９’−ジヒドロ−３’Ｈ−スピロ［シクロヘキサン−１，１’−ピラノ［３，４，ｂ］インドール］−４−アミンおよび抗けいれん剤を含む医薬組成物
AU2021295580B2 (en) Use of compounds as self-tanning substances and tanning compositions thereof
AU2007238816B2 (en) Methods for modulating formation and progression of cellulite
JP2025071027A (ja) チモールエステル系化合物を含む皮膚老化の予防または改善用組成物
KR20130028693A (ko) Ｐｄｅ5 억제제를 함유하는 피부 주름 개선용 조성물
KR102723050B1 (ko) Bcl-2 억제제를 포함하는 항노화 및 피부 미백용 조성물
JP2020502279A (ja) 色素沈着過剰障害の処置方法
HK1256597A1 (zh) 含有细胞老化抑制剂作为有效成分的皮肤皱纹改善用及皮肤损伤炎症疾病治疗用组合物
MX2007002790A (es) Combinacion de un agonista del receptor 5-hidroxitriptamina (i) y un ligando alfa-2-delta para el tratamiento de migrana.
KR101629540B1 (ko) 신규 벤조 이미다조 이미다졸 유도체 및 이를 유효성분으로 함유하는 피부 미백용 조성물
JP2008542413A (ja) ケラチン物質の色素形成の促進および／または誘発および／または刺激ならびに／あるいはそれらの色素脱失および／または脱色の制限のための２−オキシアセトアミド化合物の使用
KR20230154641A (ko) 설포라판을 유효성분으로 포함하는 피부 질환의 예방, 개선 또는 치료용 조성물
JP2025041554A (ja) チモールエステル系化合物を含む皮膚活力増強用組成物
JP2025106164A (ja) チモールエステル系化合物を含む皮膚保護用組成物
BR112018011745B1 (pt) Compostos derivados de (r)-n-(adamantil-2-il)pirrolidina-2-carboxamida para uso cosmético, composição cosmética, uso coméstico do referido composto e método para suavizar rugas e linhas de expressão e/ou para diminuir seus volume e profundidade
TW202509038A (zh) 異穿心蓮內酯（ｉｓｏａｎｄｒｏｇｒａｐｈｏｌｉｄｅ）類似物及使用其之治療方法

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: CENTRE HOSPITALIER SAINTE ANNE PARIS

Free format text: FORMER APPLICANT(S): INSTITUT PASTEUR; UNIVERSITE PARIS DESCARTES; CENTRE HOSPITALIER SAINTE ANNE PARIS

Owner name: INSTITUT PASTEUR

Free format text: FORMER APPLICANT(S): INSTITUT PASTEUR; UNIVERSITE PARIS DESCARTES; CENTRE HOSPITALIER SAINTE ANNE PARIS

Owner name: UNIVERSITE PARIS CITE

Free format text: FORMER APPLICANT(S): INSTITUT PASTEUR; UNIVERSITE PARIS DESCARTES; CENTRE HOSPITALIER SAINTE ANNE PARIS

MK25 Application lapsed reg. 22.2i(2) - failure to pay acceptance fee